新辅助化疗对乳腺癌患者调节性T细胞的影响

目的探讨新辅助化疗对乳腺癌患者外周血中CD4+CD25+Foxp3+调节性T细胞(Treg细胞)的影响。方法采集68例乳腺癌患者新辅助化疗前1d和化疗后第10天的外周静脉血,应用流式细胞仪检测外周血中Treg细胞及CD3+、CD4+及CD8+T细胞占T淋巴细胞的百分比。定量资料分别采用独立样本或配对样本t检验进行统计分析。结果化疗前,乳腺癌患者外周血Treg细胞占T淋巴细胞的百分比较健康对照组明显增高[(4.77±0.76)%比(0.68%±0.36)%,t=21.176,P=0.000]。化疗后CD4+/CD8+较化疗前升高[(1.95±0.72)%比(1.19±0.43)%,t=8.280,P=0.000];化疗后Treg细胞较化疗前明显降低[(1.59±0.58)%比(4.77±0.76)%,t=19.041,P=0.000]。化疗有效组Treg细胞较无效组明显降低,差异有统计学意义(t=8.227,P=0.000)。结论新辅助化疗可调控乳腺癌患者机体的肿瘤免疫耐受,改善其免疫功能,从而达到治疗肿瘤的效果。

Effect of neoadjuvant chemotherapy on regulatory T cells in the peripheral blood of patients with breast cancer

Objective To investigate the effect of neoadjuvant chemotherapy on CD4^＋CD25^＋Foxp3^＋T regulatory（Treg）cells in the peripheral blood of patients with breast cancer.Methods A total of 68samples of peripheral blood of patients with breast cancer were collected on the 1st day before neoadjuvant chemotherapy and the 10th day after neoadjuvant chemotherapy.The proportion of Treg,CD3^＋,CD4^＋and CD8^＋ T cells in peripheral blood in the total amount of T cells was detected by flow cytometry.Independent-sample t test or paired t test was used for the quantitative data analysis.Results The percentage of CD4^＋CD25^＋Foxp3^＋regulatory T cells in the peripheral blood of the breast cancer patients before chemotherapy（4.77±0.76）% was significantly higher than that（0.68%±0.36）%in the healthy doners（t=21.176,P=0.000）.The proportion of Treg cells in T lymphocytes was significantly decreased from（4.77±0.76）% before neoadjuvant chemotherapy to（1.59±0.58）% after neoadjuvant chemotherapy（t=19.041,P=0.000）;but CD4＋/CD8＋ was significantly increased from（1.19±0.43）%before neoadjuvant chemotherapy to（1.95±0.72）% after neoadjuvant chemotherapy（t=8.280,P=0.000）.The treg cells in the chemotherapy-effective group were significantly decreased compared with the chemotherapy-ineffective group,with a statistical difference between the two groups（t=8.227,P=0.000）.Conclusions Neoadjuvant chemotherapy can regulate the immune-tolerance of breast cancer patients,and improve their immune function.Neoadjuvant chemotherapy may inhibit tumor through reducing Treg cells in the peripheral blood of patients with breast cancer.